Recruiting × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × 1 year × Clear all Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Phase 1 Recruiting
86 enrolled
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
Phase 2 Recruiting
22 enrolled
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
Phase 2 Recruiting
30 enrolled
Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).
Phase 1/2 Recruiting
33 enrolled
CARxALL
Phase 1 Recruiting
20 enrolled
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
Phase 1/2 Recruiting
54 enrolled
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
Phase 2 Recruiting
134 enrolled
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Phase 2 Recruiting
20 enrolled
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Recruiting
1,263 enrolled
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Phase 1 Recruiting
12 enrolled
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Phase 2 Recruiting
44 enrolled
Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
Phase 2 Recruiting
40 enrolled
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase 2 Recruiting
160 enrolled
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Phase 2 Recruiting
125 enrolled
24CT015
Phase 1 Recruiting
33 enrolled
FRACTALL
Phase 1 Recruiting
24 enrolled
Novel Therapeutic Approach for Human T-cell Malignancies
Recruiting
120 enrolled
CD7-CAR01
Phase 1/2 Recruiting
26 enrolled
Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation
Phase 2 Recruiting
15 enrolled
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
Phase 1/2 Recruiting
80 enrolled
nanobody CD5
Phase 1/2 Recruiting
54 enrolled
A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma
Phase 1/2 Recruiting
49 enrolled
Two Step Haplo With Radiation Conditioning
Phase 2 Recruiting
63 enrolled
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Recruiting
15,000 enrolled
Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
Phase 1 Recruiting
27 enrolled
CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
Phase 1 Recruiting
108 enrolled
HEM-iSMART D
Phase 1/2 Recruiting
26 enrolled
HEM-iSMART C
Phase 1/2 Recruiting
26 enrolled
HEM-iSMART B
Phase 1/2 Recruiting
26 enrolled
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
Phase 2 Recruiting
27 enrolled
MAGENTA
Phase 1 Recruiting
54 enrolled
CCCG-TALL-2025
Phase 2/3 Recruiting
610 enrolled
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
Phase 1/2 Recruiting
67 enrolled
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Recruiting
Registry of Older Patients With Cancer
Recruiting
3,000 enrolled
DARA_T_ALL
Phase 2 Recruiting
18 enrolled
Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
Phase 2 Recruiting
32 enrolled
A Registry for People With T-cell Lymphoma
Recruiting
1,000 enrolled
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Phase 1/2 Recruiting
85 enrolled
Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
Phase 2 Recruiting
59 enrolled
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Phase 1 Recruiting
36 enrolled
Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies
Phase 1 Recruiting
15 enrolled